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Abstract
Introduction: Pregnant women exposed chronically to opioids smoked more cigarettes per day 
(CPD) and had a higher nicotine metabolite ratio (NMR), 3-hydroxycotinine/cotinine, a biomarker 
of nicotine metabolism and clearance, than those not receiving opioids. We examined CPD and 
NMR in a group of pregnant smokers, a quarter of whom were receiving opioid agonist therapy 
(OAT).
Aims and Methods: Pregnant smokers recruited to participate in a placebo-controlled trial of bu-
propion for smoking cessation provided a blood sample for measurement of NMR.
Results: Half (52.4%) of the 124 women with NMR data were African American. OAT-treated 
women (n = 34, 27.4%; 27 receiving methadone and 7 buprenorphine) were more likely to be white 
(79% vs. 30%, p < .001) and to have a lower mean PHQ-9 total score (2.91 [SD = 2.83] vs. 4.83 
[SD = 3.82], p = .007). OAT-treated women reported smoking more CPD (9.50 [SD = 5.26] vs. 7.20 
[SD = 3.65], p = .005) and had higher NMR (0.78 [SD = 0.36] vs. 0.56 [SD = 0.25], p = .001) than the 
non-OAT-treated group. In a linear regression analysis adjusting for race, depression severity, and 
CPD, NMR was greater in the OAT group (p = .025), among whom the daily methadone-equivalent 
dosage correlated with NMR (Spearman’s ρ = 0.49, p = .003).
Conclusions: Consistent with the findings of Oncken et  al. (2019), we found that OAT smokers 
smoked more and had higher NMR than non-OAT smokers. As higher NMR is associated with a re-
duced likelihood of smoking cessation, the effects on NMR of both pregnancy and OAT could con-
tribute to a lower smoking cessation rate in pregnant smokers receiving chronic opioid therapy.
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Implications: We replicated the finding that the NMR is significantly greater among pregnant 
smokers receiving OAT than those not receiving this treatment for opioid use disorder. Furthermore, 
we found that the dosage of the OAT was significantly associated with the NMR level. These find-
ings may contribute to a poorer response to smoking cessation treatment in pregnant women 
treated with OAT, particularly those receiving high-dose therapy, and raise the question of whether 
novel approaches are needed to treat smoking in this subgroup of pregnant smokers.
Introduction
In 2016, 9.4% of U.S. women reported smoking before becoming 
pregnant, with rates decreasing during pregnancy.1 Nonetheless, cig-
arette smoking during pregnancy is estimated to contribute to 5.3%–
7.7% of preterm deliveries, 13.1%–19.0% of low-birth-weight 
deliveries, 23.2%–33.6% of cases of sudden infant death syndrome, 
and 5.0%–7.3% of preterm-related deaths.2 When treated with 
FDA-approved medications for tobacco use, pregnant smokers show 
lower rates of smoking cessation than nonpregnant women.3 This is 
due, in part, to the induction of the enzymes CYP2A6 and UGT2B10 
and a higher rate of nicotine metabolism, which begins by 12 weeks 
of gestation and continues throughout pregnancy.4,5
The ratio of the nicotine metabolites 3′-hydroxycotinine (3HC) 
to cotinine (nicotine metabolite ratio [NMR]) reflects the rate of 
nicotine metabolism and clearance. The NMR is largely determined 
by the activity of CYP2A6, encoded by the gene CYP2A6, and 
other genetic and environmental influences.6,7 The NMR is highly 
reproducible and independent of the time since the last cigarette.8 
Importantly, slow metabolizers of nicotine have significantly higher 
quit rates than faster metabolizers, both in the absence of pharma-
cotherapy and with nicotine replacement therapy and in smokers of 
both European9 and African ancestry.10
Opioid use disorder (OUD) is also an important factor contrib-
uting to the effectiveness of smoking cessation efforts. For example, 
methadone-maintained OUD patients have a smoking prevalence 
that is about fourfold and sustained smoking cessation rates with 
treatment half or less that of the general population.11 As in the 
general population, opioid use in pregnancy has increased dramatic-
ally in recent years.12 Although opioid agonist therapy (OAT) is the 
recommended treatment for OUD during pregnancy, chronic opioid 
exposure appears to augment the effects of pregnancy on NMR.13 
Thus, efforts to promote smoking cessation during pregnancy among 
women receiving OAT may be less successful than among pregnant 
smokers not receiving OAT. In the present study, we examined the 
daily smoking rate and NMR in pregnant smokers differentiated by 
the presence or absence of OAT.
Methods
Participants
Subjects (N  =  129) were recruited to participate in a randomized, 
placebo-controlled trial of bupropion for smoking cessation among 
pregnant smokers (clinicaltrials.gov: NCT02188459). They were eli-
gible to participate if they smoked at least 3 cigarettes per day (CPD) 
for the preceding 7  days, wanted to quit smoking, were at 13–26 
weeks of gestation, at least 18 years old, able to speak English, and 
able to sign written informed consent and commit to completing the 
study procedures. We excluded individuals with a current substance 
use disorder other than nicotine and opioid use disorders, including 
alcohol use disorder, multiple gestations other than twins, an unstable 
psychiatric or medical problem, current use of psychotropic medica-
tion, a known congenital abnormality, a history of a seizure disorder, 
current use of any other smoking cessation medication, anorexia or 
bulimia, or use of other tobacco products. The study was approved 
by institutional review boards at all participating centers and was 
conducted from October 30, 2014 through January 22, 2020.
The current analyses include 124 pregnant smokers with bio-
marker data at baseline. We excluded five participants whose NMR 
could not be calculated, either because a blood sample could not be 
obtained (n = 1) or their cotinine and 3HC levels were below the 
level of quantification (n = 4).
Procedure and Measures
Baseline demographic and clinical variables included age, race, 
marital status, gestational age (in weeks), and depression symptom 
severity (measured using the nine-item Patient Health Questionnaire 
or PHQ-914). We obtained a medication history and OAT was iden-
tified through self-report and medical record review. At baseline, 
the average number of cigarettes smoked per day in the past 7 days 
was assessed by self-report, and the Fagerström Test for Cigarette 
Dependence (FTCD) was administered.15
Analytic Chemistry
Serum samples were assayed for the concentration of nicotine, 
cotinine, and trans-3HC by Liquid Chromatography with tandem 
mass spectrometry as previously described8 with limits of quantifi-
cation of 1.0 ng/mL whole blood for each compound. We excluded 
individuals with cotinine less than 10  ng/mL, which is suggestive 
of non-daily smoking16 and yields unstable NMR measurements be-
cause cotinine is not at a steady state.
Data Analysis
NMR was calculated as the ratio of 3HC/cotinine. In bivariate ana-
lyses, we tested differences in baseline characteristics by OAT status 
using Wilcoxon tests for continuous variables and chi-square tests 
for categorical variables. The distribution of NMR showed low 
levels of skewness in both the OAT (skew  =  0.21) and non-OAT 
(skew  =  0.24) groups, with no outliers, so we analyzed the raw 
NMR score. We conducted multivariable linear regression to deter-
mine the associations between NMR and OAT status, with CPD, 
PHQ-9 total, and race included as covariates, as they differed signifi-
cantly by OAT status. For the regression analysis, we report the un-
standardized regression coefficients, corresponding to the difference 
in NMR mean between the OAT and non-OAT groups, adjusting 
for the covariates. Because the distribution of OAT users differed by 
race, in a secondary regression analysis, we examined the interaction 
of race with OAT status on NMR.
Additionally, within the OAT group, we examined the asso-
ciations between OAT daily dose and NMR using the daily dose 
reported by participants (in milligrams). To establish equivalence 
between dosing of methadone and buprenorphine, we multiplied 
the buprenorphine daily doses by 5.17 To accommodate an outlier 
on daily dose in the methadone group, we used Spearman rank 
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correlations to summarize the association between NMR and daily 
dose level within each group, with a robust regression method (using 
a bisquare weight function) to test for main effects of daily dose and 
interactions with OAT type.
We performed all analyses using SAS/STAT software, version 9.4 
(SAS Institute Inc., Cary, NC).
Results
Table 1 shows the baseline demographic and clinical characteristics of 
the 124 pregnant smokers included in the analyses comparing the OAT 
and non-OAT groups. The groups were similar on mean age (29.91 
[SD = 5.29] and 27.96 [SD = 4.63] years in the OAT and non-OAT 
groups, respectively) and the likelihood of ever having married (41% 
vs. 38%, respectively). However, the racial composition of the groups 
differed significantly, with the OAT group predominantly (79%) of 
European ancestry and the non-OAT group predominantly (64%) of 
African ancestry. The non-OAT group had a higher mean PHQ-9 total 
score (4.83 [SD = 3.82]) than the OAT group (2.91 [SD = 2.83]). The 
mean number of CPD was significantly higher in the OAT group (9.50 
[SD = 5.26]) than the non-OAT group (7.20 [SD = 3.65]), although 
the FTCD total score was not (4.15 [SD = 1.99] in the OAT group 
and 3.71 [SD  =  1.80] in the non-OAT group). The gestational age 
did not differ by group, which obviated controlling for this potential 
effect on NMR.5 Most patients in the OAT group were being treated 
with methadone (n  =  27 or 79.4%; mean daily dosage  =  91.0  mg 
[SD = 62.6]) with the remainder receiving buprenorphine (n = 7 or 
20.6%; mean daily dosage = 14.3 mg [SD = 3.2]). One participant re-
ported a confirmed daily methadone dose of 360 mg; for the other 26 
participants, the mean daily dose was 80.62 mg (SD = 32.70).
Nicotine Metabolite Concentrations and Ratio
Blood cotinine concentration did not differ by OAT status 
(105.16 ng [SD = 61.70] and 111.13 ng [SD = 70.89] in the OAT 
and non-OAT groups, respectively), with a nonsignificant trend 
(p  =  .074) for a greater concentration of 3HC in the OAT group 
(73.62 ng/mL [SD  =  50.39]) than the non-OAT group (57.54 ng/
mL [SD  =  44.18]). The mean NMR was significantly greater in 
the OAT group (0.78 [SD = 0.25]) than the non-OAT group (0.56 
[SD = 0.25]), though within the OAT group, the mean NMR did not 
differ between methadone-treated women (0.78 [SD = 0.40]) and the 
buprenorphine-treated women (0.76 [SD = 0.12], p = .98).
Predictors of NMR
The results of the linear regression model of NMR adjusted for race, 
PHQ-9 score, and CPD are presented in Table 2. The OAT group 
had a higher NMR than the non-OAT group (b = 0.14, SE = 0.06, 
p  =  .025), with African American (AA) women having a lower 
NMR than European American (EA) women (b = −0.15, SE = 0.05, 
p = .008). We conducted a secondary analysis that was restricted to 
the 65 AAs and 54 EAs (which exclude five individuals of “other” 
race), which yielded results very similar to those in the full sample: 
the expected NMR value among the OAT is 0.15 (SE = 0.06) larger 
than in OAT nonusers (p = .016). Within this reduced sample of 118, 
there are 7 AAs (10.8%) and 27 EAs (50.0%) who were receiving 
OAT, a distribution within populations that yields lower power than 
a more even distribution would. An analysis of the interaction of 
race by OAT was not significant: χ21 = 0.59, p =  .44. Within AAs, 
there is a small, nonsignificant effect: the expected NMR value 
among OAT users is 0.08 (SE = 0.11) larger than in OAT nonusers 
Table 1. Pretreatment Demographic and Clinical Variables by Opioid Agonist Therapy (OAT) Status (N = 124)
OAT status
Non-OAT OAT pa
Age in years, mean (SD) 28.0 (4.6) 29.9 (5.3) .087
Race, n (%)   <.0001
 AA/black 58 (64%) 7 (21%) —
 EA/white 27 (30%) 27 (79%) —
 Other 5 (6%) 0 (0%) —
Marital status, n (%)   .73
 Never married 56 (62%) 20 (59%) —
 Ever married 34 (38%) 14 (41%) —
Gestational age in weeks, mean (SD) 21.1 (3.9) 20.6 (4.6) .78
PHQ-9 total score, mean (SD) 4.8 (3.8) 2.9 (2.8) .007
Cigarettes/day, mean (SD) 7.2 (3.6) 9.5 (5.3) .005
FTCD total score, mean (SD) 3.7 (1.8) 4.1 (2.0) .36
Serum cotinine (ng/mL), mean (SD) 111.1 (70.9) 105.2 (61.7) .87
Serum 3HC (ng/mL), mean (SD) 57.5 (44.2) 73.6 (50.4) .074
Nicotine metabolite ratio, mean (SD) 0.6 (0.3) 0.8 (0.4) .001
SD = standard deviation; AA = African American; EA = European American; FTCD = Fagerström Test for Cigarette Dependence; 3HC = 3-hydroxycotinine; 
PHQ-9 = Patient Health Questionnaire-9. Numbers in bold are statistically significant.
ap-values calculated using F-test for continuous variables and chi-square statistic for categorical variables.
Table 2. Multivariable Linear Regression Model of Nicotine 
Metabolite Ratio as a Function of Opioid Agonist Therapy Status, 
Depression Severity, Race, and Smoking Intensity (N = 124)a
β coefficientb SE p
Opioid agonist therapy 0.14 0.06 .025
Cigarettes per day (CPD) −0.0006 0.006 .920
PHQ-9 score −0.006 0.007 .373
Race/ethnicity (vs. white)
 African American −0.15 0.05 .008
 Other/Refused −0.02 0.13 .859
SE = standard error.
aPredictors: opioid agonist therapy and CPD; covariates: Patient Health 
Questionnaire-9 (PHQ-9) and race.
bWe report the unstandardized regression coefficient.
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(p = .47). Within EAs, the expected NMR value among OAT users is 
0.18 (SE = 0.08, p = .015) larger than in OAT nonusers, results that 
were similar to those in the full sample.
Neither CPD nor PHQ-9 score was associated with NMR. 
Although changes in NMR have been observed across pregnancy,5 
we tested women at approximately the same gestational age.
Among women receiving OAT (n = 34), a higher OAT dose was 
associated with higher NMR levels (Spearman’s ρ = 0.49, p = .003). 
The associations were of a similar magnitude within the methadone-
only (n = 27, ρ = 0.50, p = .05) and the buprenorphine-only (n = 7, 
ρ = 0.45, p =  .31) subgroups. In the main-effect robust regression 
model, there was a significant positive association (β  =  0.002, 
SE = 0.001, p = .044) between daily OAT dose and NMR, but no 
interaction of dose × OAT subgroup (p = .95).
Discussion
After controlling for relevant covariates, we found that the use of 
OAT was associated with higher NMR among pregnant smokers. 
Specifically, although cotinine levels were similar among smokers 
irrespective of OAT, 3HC levels were marginally higher and NMR 
was significantly higher among OAT smokers, findings that are 
consistent with those of Oncken et  al.13 In contrast to the prior 
report, however, in which the NMR value was nominally greater 
among women treated with methadone (56% of the sample; median 
NMR = 0.63) than among those receiving buprenorphine (32% of 
the sample; median NMR = 0.55), the two OAT medication groups 
in our sample were nearly identical on NMR (methadone: 79.4% 
of the sample; NMR = 0.78; buprenorphine 21.6%; NMR = 0.76). 
We also found a moderate (ρ = 0.49), but significant, correlation 
between the dosage of OAT and NMR, consistent with a pharma-
cological effect of OAT on NMR.
We found a nominally larger effect of OAT on NMR in EAs than 
AAs. However, because of the small number of AAs who were re-
ceiving OAT (n = 7), we cannot draw a conclusion as to whether race 
affects OAT’s impact to increase NMR during pregnancy. Future 
studies in larger samples of AAs who are receiving OAT are needed 
to evaluate the racial difference.
The prevalence and persistence of cigarette smoking in individ-
uals with OUD far exceed that of the general U.S. adult population18 
and the severity of nicotine dependence is significantly greater than 
that among smokers without OUD.19 As reviewed above, a more 
rapid nicotine metabolism, reflected by a higher NMR, is associ-
ated with a lower likelihood of smoking cessation. Thus, in addition 
to the increase in NMR associated with pregnancy, chronic opioid 
exposure also appears to increase NMR, and thus likely increases 
nicotine metabolism. These may jointly contribute to the poorer re-
sponse to smoking cessation treatment seen among pregnant women 
with OUD.
The mechanism by which OAT increases the NMR during preg-
nancy remains to be determined. It could be via induced CYP2A6, but 
opioids also compete in a dose-dependent manner for 5′-diphospho-
glucuronosyltransferase (UGT) enzymes,20 which metabolize 3HC to 
3HC glucuronide for excretion. Chronic opioid exposure is associ-
ated with lower 3HC metabolism, which increases NMR, an effect 
that is consistent with the correlation observed here between OAT 
dose and NMR.
Oncken et al.13 found a significant association of opioid exposure 
and NMR only for methadone. In our sample, the NMR values for 
the methadone- and buprenorphine-treated groups were similar. 
Given the small number of buprenorphine-treated women in both 
studies, further research on the effects of chronic opioid exposure on 
NMR in pregnant smokers is warranted in samples large enough to 
compare the effects of different opioids.
We found a moderate correlation between OAT dosage and 
NMR, which was comparable in magnitude in the methadone and 
buprenorphine groups. This contrasts with a study of nonpregnant 
smokers maintained on buprenorphine, in which there was no ef-
fect of the drug’s dosage on NMR.21 Our study was limited by the 
small number of smokers receiving OAT. Furthermore, although we 
controlled for a variety of potential confounders, we did not have 
information on whether the participants smoked menthol cigarettes, 
which can affect nicotine metabolism; Oncken et al.13 found no such 
effect of menthol cigarettes. Further research is needed to determine 
whether a dose–response relationship that appears to exist for OAT 
differs with the specific maintenance medication and the impact of 
menthol cigarettes on this relationship.
In summary, we replicated the reported finding that pregnant 
smokers receiving chronic opioid therapy have a higher NMR than 
pregnant smokers not receiving opioids.13 The moderate correlation 
that we observed between the dosage of OAT and NMR is consistent 
with a pharmacokinetic interaction between nicotine and chronic 
opioid therapy. Further research is needed to replicate these find-
ings in a larger sample of pregnant smokers receiving OAT, so as to 
ascertain whether there are different effects among opioid drugs, to 
identify other factors that potentially affect NMR, and to elucidate 
the mechanisms by which these effects occur.
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